New Hope for Alzheimer's Treatment Found in a Small Protein

Topic: Health

Scientists at ETH Zurich discovered a protein called GRK2 that may be causing Alzheimer's disease. They found a way to block it with a new compound, Compound 10.

Ursula Quitterer and her team at ETH Zurich have been working on a treatment for Alzheimer's disease for nearly 20 years. They started by studying brain tissue samples from patients who had dementia and those who didn't. The samples came from Ain Shams University Hospital in Cairo, where a doctor and colleague of Quitterer's had removed them during tumor surgery.

The team focused on an enzyme called GRK2, which helps cells respond to signals and stress. They found that GRK2 plays a big role in dementia and that it exists in two forms: one normal and functional, the other inactive. In people with dementia, they saw unusually large amounts of the inactive form.

In mice, Quitterer's team also found that inactive GRK2 can clump together inside brain cells during dementia. These aggregates block the pores of mitochondria, reducing energy supply and causing stress in cells. They also discovered that inactive GRK2 increases production of amyloid beta, a protein fragment that contributes to Alzheimer's.

To interrupt this process, Quitterer's team created several chemical compounds and tested them in cell cultures and mice. Compound 10 stood out as particularly effective. It prevented GRK2 molecules from forming aggregates, allowing mitochondria to function better and reducing amyloid beta accumulation.

Why It Matters

This discovery could lead to a new treatment for Alzheimer's disease, which affects millions of people worldwide. If successful, it could improve the lives of those suffering from this devastating condition.

Key Facts

• Ursula Quitterer and her team at ETH Zurich discovered that GRK2 may be causing Alzheimer's disease.
• They found a way to block GRK2 with a new compound called Compound 10.
• Compound 10 has shown promising results in mice, preventing GRK2 molecules from forming aggregates and reducing amyloid beta accumulation.
• The team started studying brain tissue samples nearly 20 years ago at Ain Shams University Hospital in Cairo.
• GRK2 exists in two forms: one normal and functional, the other inactive.

Key Terms

Mitochondria

The 'powerhouses' of cells that produce energy.

Implications

This discovery could lead to a new treatment for Alzheimer's disease, which affects millions of people worldwide. If successful, it could improve the lives of those suffering from this devastating condition.